KMT2A and cancer: A significant portion of high-risk acute leukemia patients, especially those with KMT2A/MLL-R+ ALL or AML relapse after being treated on contemporary chemotherapy protocols due to cancer drug resistance of their leukemic clones, and the survival outcome of available salvage regimens is disappointing due to the short nature and poor quality of second remissions.